Nacuity Pharmaceuticals
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
306 W 7th St Ste 310, Fort Worth, Texas,...Phone Number
(817) 336-3000Website
www.nacuity.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Nacuity Pharmaceuticals
Nacuity Pharmaceuticals is a leader in developing innovative treatments aimed at stopping oxidative tissue damage, which is a significant factor in blinding eye diseases and various chronic conditions. The company focuses on targeted therapies and has several differentiated clinical programs, including those for retinitis pigmentosa, cataract, and cystinosis. Their intended clients include patients suffering from these eye diseases and healthcare providers seeking advanced treatment options. Nacuity's commitment to addressing oxidative stress positions it as a key player in the pharmaceutical industry.Explore more
Nacuity Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nacuity Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Nacuity Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Nacuity Pharmaceuticals has new funding data
Nacuity Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Nacuity Pharmaceuticals launches new products
Check if Nacuity Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Nacuity Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Nacuity Pharmaceuticals
Earning: See what the market has to say on Nacuity Pharmaceuticals recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Nacuity Pharmaceuticals
Compare insights from companies similar to Nacuity Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nacuity Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nacuity Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nacuity Pharmaceuticals.
Nacuity Pharmaceuticals financials insights
Gather financial insights about Nacuity Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$16.5M
Nacuity Pharmaceuticals Tech Stack
A closer look at the technologies used by Nacuity Pharmaceuticals
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Nacuity Pharmaceuticals News & Media
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two yearsNacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa
FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy for the treatment of patients with retinitis pigmentosa (RP).Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
Two patients have been implanted in the final cohort of the trial
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nacuity Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Nacuity Pharmaceuticals is a leader in developing innovative treatments aimed at stopping oxidative tissue damage, which is a significant factor in blinding eye diseases and various chronic conditions. The company focuses on targeted therapies and has several differentiated clinical programs, including those for retinitis pigmentosa, cataract, and... Read More
